rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Xeris Biopharma Holdings, Inc.

XERS · Nasdaq

Health CareBiotechnologyLeading

XERS stood above a rising 150-day average in 29 of the last 52 weekly readings, including each of the last 15 weeks. It is 37.7% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
15 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$8.9M
Officials’ trades on record
0
Institutions holding
226 (+11)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 29 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.4M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months32
Buyers · sellers0 · 9
WhoDidSharesTraded
Beth HechtOfficersold16,666at $9.411 Oct 2026filed 2 Oct 2026
Kevin McCullochOfficersold15,000at $9.411 Oct 2026filed 2 Oct 2026
Steven PieperOfficersold5,000at $9.411 Oct 2026filed 2 Oct 2026
Kevin McCullochOfficersold25,000at $10.0028 Sep 2026filed 29 Sep 2026
Beth HechtOfficersold16,666at $8.491 Sep 2026filed 1 Sep 2026
Steven PieperOfficersold5,000at $8.501 Sep 2026filed 1 Sep 2026
Kevin McCullochOfficersold15,000at $8.491 Sep 2026filed 1 Sep 2026
Steven PieperOfficersold5,000at $8.5012 Aug 2026filed 12 Aug 2026
Beth HechtOfficersold16,666at $8.013 Aug 2026filed 4 Aug 2026
Kevin McCullochOfficersold15,000at $8.023 Aug 2026filed 4 Aug 2026
Steven PieperOfficersold27,600at $8.527 Jul 2026filed 7 Jul 2026
Steven PieperOfficersold17,400at $8.506 Jul 2026filed 7 Jul 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders226+11 on the quarter
New · exited41 · 31
Reported value$859.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202614,525,539$115.0M+1,579,754+12.2%
D. E. Shaw & Co., Inc.added · filed 14 Aug 20267,804,758$61.8M+15,947+0.2%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 20267,340,229$58.1M+7,340,229
STATE STREET CORPadded · filed 7 Aug 20264,821,566$38.2M+163,392+3.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20264,718,183$37.4M+427,554+10.0%
Nuveen, LLCadded · filed 11 Aug 20264,385,141$34.7M+1,468,543+50.4%
Rosalind Advisors, Inc.reduced · filed 14 Aug 20262,908,981$23.0M-322,719−10.0%
Qube Research & Technologies Ltdreduced · filed 14 Aug 20262,893,749$22.9M-1,220,676−29.7%
VANGUARD PORTFOLIO MANAGEMENT LLCnew · filed 13 Aug 20262,626,208$20.8M+2,626,208
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 20262,365,103$18.7M+193,749+8.9%
31 Mar 2023 – 30 Jun 2026
75148220Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Beth Hecht Company insiderOfficer · last 1 Oct 20260 · 13
Kevin McCulloch Company insiderOfficer · last 1 Oct 20261 · 6
Steven Pieper Company insiderOfficer · last 1 Oct 20262 · 5
John Patrick Shannon Jr. Company insiderDirector, Officer · last 1 Aug 20263 · 2
Nerissa Kreher Company insiderDirector · last 1 Jul 20260 · 0
Barbara-Jean Anne Bormann-Kennedy Company insiderDirector · last 4 Jun 20260 · 2
Dawn Halkuff Company insiderDirector · last 4 Jun 20261 · 2
Garheng Kong Company insiderDirector · last 4 Jun 20260 · 0
James Aloysius Brady Company insiderDirector · last 4 Jun 20260 · 1
John Johnson Company insiderDirector · last 4 Jun 20260 · 3
Marla Persky Company insiderDirector · last 4 Jun 20261 · 2
Anh Tu Nguyen Company insiderOfficer · last 24 Feb 20260 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 20258.5%
Return on capital employedFY 2025 · to 31 Dec 20259.1%
Debt to equityFY 2025 · to 31 Dec 202516.10×
Research spendFY 2025 · to 31 Dec 202510.7%
Share count trendFY 2025 · to 27 Feb 20263.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$111.0M

Analyst forecasts

No analyst forecasts yet.